Dr. Mehra is Managing Director at Global Drug Development Experts where he leads a team in the U.S. and a SMO in India to accelerate drug development through rapid patient enrollment. He is a Senior Clinical Researcher with twenty five years of experience in conducting clinical trials.
Dr. Ball is Director, Division of Scientific Investigations, CDER, FDA. She joined the FDA in 1996. Dr. Ball graduated from Georgetown University School of Medicine, where she completed a residency in Pediatrics. She completed a fellowship in Pediatric Infectious Diseases at Walter Reed.
PhD in pharmacology 1986 Joined EMEA in 1999. Coordination of GCP and Pharmacovigilance inspection. Chairman of the GCP Inspectors Working Group and Ad Hoc Pharmacovigilance Inspectors Working Group. Business analyst for the EudraCT database.
Description
This showcase will bring together regulatory authority compliance experts from FDA and EMA who will share their perspective on inspections and common areas of GCP noncompliance. Developed by the Good Clinical Practice and Quality Assurance (GCP) SIAC.
Learning Objectives: Discuss frequently occurring GCP violations from FDA inspections Identify what to focus on from a GCP compliance standpoint.